2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1714 Dynamic immune remodeling and mast cell states predict survival in pediatric acute myeloid leukemia

Jaclyn R Shaw, Ryanne June Mulligan, BS2, Rhonda E. Ries, MA3, Soheil Meshinchi, MD, PhD4, Jatinder K Lamba, PhD5
1 University of Florida, Gainesville, Florida, United States
2 University of Florida, Gainesville, Florida, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 University of Florida Health Cancer Institute, Gainesville, Florida, United States, University of Florida, Gainesville, Florida, United States

Background: The immune microenvironment influences disease biology and survival in acute myeloid leukemia (AML), yet the immune cell composition of pediatric AML and its evolution at relapse remain poorly characterized.

Aims: To define immune cell abundance at diagnosis and relapse in pediatric AML and evaluate associations with AML subtype, survival, and hematopoietic stem cell transplantation (HSCT) outcomes.

Methods: Bulk RNA-sequencing and clinical data from 1,520 pediatric AML patients enrolled on Children's Oncology Group (COG) trials were obtained from TARGET-AML. Relative abundances of 22 immune cell populations were estimated using CIBERSORTx. Associations between immune cell fractions and clinical characteristics, overall survival (OS), and event-free survival (EFS) were assessed. Paired diagnosis-relapse specimens from 285 patients (350 relapse samples) were analyzed to identify immune landscape changes at relapse. HSCT analyses were performed in 162 patients treated on AAML1031.

Results: Immune cell composition differed significantly between diagnosis and relapse. Relapse samples demonstrated significantly lower fractions of resting mast cells, naïve CD4 T cells, monocytes, memory B cells, M2 macrophages, and eosinophils, whereas resting memory CD4 T cells, activated memory CD4 T cells, regulatory T cells, naïve B cells, and M0 macrophages were increased (all P<0.01).

At diagnosis, immune cell abundance was independently associated with clinical outcome. Higher activated mast cell abundance predicted inferior OS (HR=1.26, P=0.038), whereas higher resting mast cell abundance predicted superior OS (HR=0.62, P=1.38×10?6). Increased monocyte abundance was associated with worse EFS (HR=1.16, P=0.036), while higher resting NK cell abundance predicted improved EFS (HR=0.71, P=0.019).

Immune cell abundance at relapse showed, higher fractions of CD8 T cells (HR=0.72, P=0.038), naïve CD4 T cells (HR=0.49, P=0.002), resting mast cells (HR=0.53, P=1.69×10?4), and resting NK cells (HR=0.63, P=0.002) were associated with improved post-relapse OS. Conversely, activated NK cells (HR=2.34, P=1.56×10?4), activated mast cells (HR=2.43, P=6.63×10?4), and monocytes (HR=1.63, P=8.34×10?4) predicted inferior survival.

Among HSCT recipients, diagnosis-derived immune cell composition remained prognostic in predicting survival from time of HSCT. Higher naïve B-cell and follicular helper T-cell abundance predicted inferior OS and EFS, whereas higher resting mast cell abundance predicted improved OS (HR=0.43, P=0.023), regulatory T cells predicted improved EFS (HR=0.52, P=0.020), and activated mast cells predicted inferior EFS (HR=1.84, P=0.043). Significant differences in immune cell composition were also observed across FAB and cytogenetic subgroups.

Conclusions: This study provides the first comprehensive characterization of immune cell abundance across diagnosis and relapse in pediatric AML and demonstrates that immune composition is strongly associated with disease subtype, survival, and HSCT outcomes. Resting and activated mast cells emerged as the most consistent prognostic immune populations across multiple clinical settings, highlighting mast cell biology as a potential determinant of AML progression and therapeutic response. These findings identify immune cell composition as a promising biomarker for risk stratification and support ongoing validation in independent pediatric AML cohorts.

Jaclyn R Shaw: No relevant conflicts of interest to declare.